SHARE-BASED COMPENSATION	9 Months Ended
Jun. 30, 2022
Share-Based Payment Arrangement [Abstract]
SHARE-BASED COMPENSATION	NOTE 6 SHARE-BASED COMPENSATION Stock Options In October 2021, January 2022 and April 2022, the Company granted options to non-employee directors to purchase an aggregate of 58,000, 83,000 and 49,000 shares, respectively, of its common stock at an exercise price of $2.39, $1.56 and $1.72 per share, respectively. The options expire five years from the date of grant, approximately half vested immediately and approximately half vest one year from the date of grant. The options have a weighted average grant-date fair value of $1.03, $0.72 and $0.81 per share, respectively, and an aggregate grant date fair value of $60,000, $60,000 and $40,000, respectively, which will be recognized ratably over the vesting period. In January 2022, the Company granted options to one of its employees to purchase an aggregate of 14,000 shares of its common stock at an exercise price of $1.56 per share. The options expire five years from the date of grant, approximately one-third vested immediately, approximately one-third vest one year from the date of grant and approximately one-third vest two years from the date of grant. The options have a weighted average grant-date fair value of $0.73 per share and an aggregate grant-date fair value of $10,000, which will be recognized ratably over the vesting period. In February 2022, the Company granted options to one of its non-employee directors to purchase an aggregate of 31,000 shares of its common stock at an exercise price of $1.68 per share. The options vest one year from the date of grant and expire five years from the date of grant. The options have a weighted average grant-date fair value of $0.80 per share and an aggregate grant-date fair value of $25,000, which will be recognized ratably over the vesting period. In February 2022, the Company granted options to one of its former non-employee directors to purchase an aggregate of 19,000 shares of its common stock at an exercise price of $1.68 per share. The options vested immediately and expire ten years from the date of grant. The options have a grant-date fair value of $1.07 per share and an aggregate grant-date fair value of $20,000, which was fully recognized on the grant date. There were no options exercised during the nine months ended June 30, 2022. During the nine months ended June 30, 2021, the Company issued 147,000 shares of its common stock pursuant to the exercise of stock options for aggregate cash proceeds of $234,000, which had an aggregate intrinsic value of $265,000. The Company recognized compensation expense for stock option awards of $44,000 and $4,000 during the three months ended June 30, 2022 and 2021, respectively, and $148,000 and $66,000 during the nine months ended June 30, 2022 and 2021, respectively, which was recorded as a component of general and administrative expenses in its condensed consolidated statements of operations. At June 30, 2022, there was $51,000 of total unrecognized compensation cost related to nonvested stock option awards that is expected to be recognized over a weighted average period of 0.6 years.

SHARE-BASED COMPENSATION

9 Months Ended

Jun. 30, 2022

Share-Based Payment Arrangement [Abstract]

NOTE 6 SHARE-BASED COMPENSATION

Stock Options

In October 2021, January 2022 and April 2022, the Company granted options to non-employee directors to purchase an aggregate of 58,000, 83,000 and 49,000 shares, respectively, of its common stock at an exercise price of $2.39, $1.56 and $1.72 per share, respectively. The options expire five years from the date of grant, approximately half vested immediately and approximately half vest one year from the date of grant. The options have a weighted average grant-date fair value of $1.03, $0.72 and $0.81 per share, respectively, and an aggregate grant date fair value of $60,000, $60,000 and $40,000, respectively, which will be recognized ratably over the vesting period.

In January 2022, the Company granted options to one of its employees to purchase an aggregate of 14,000 shares of its common stock at an exercise price of $1.56 per share. The options expire five years from the date of grant, approximately one-third vested immediately, approximately one-third vest one year from the date of grant and approximately one-third vest two years from the date of grant. The options have a weighted average grant-date fair value of $0.73 per share and an aggregate grant-date fair value of $10,000, which will be recognized ratably over the vesting period.

In February 2022, the Company granted options to one of its non-employee directors to purchase an aggregate of 31,000 shares of its common stock at an exercise price of $1.68 per share. The options vest one year from the date of grant and expire five years from the date of grant. The options have a weighted average grant-date fair value of $0.80 per share and an aggregate grant-date fair value of $25,000, which will be recognized ratably over the vesting period.

In February 2022, the Company granted options to one of its former non-employee directors to purchase an aggregate of 19,000 shares of its common stock at an exercise price of $1.68 per share. The options vested immediately and expire ten years from the date of grant. The options have a grant-date fair value of $1.07 per share and an aggregate grant-date fair value of $20,000, which was fully recognized on the grant date.

There were no options exercised during the nine months ended June 30, 2022. During the nine months ended June 30, 2021, the Company issued 147,000 shares of its common stock pursuant to the exercise of stock options for aggregate cash proceeds of $234,000, which had an aggregate intrinsic value of $265,000.

The Company recognized compensation expense for stock option awards of $44,000 and $4,000 during the three months ended June 30, 2022 and 2021, respectively, and $148,000 and $66,000 during the nine months ended June 30, 2022 and 2021, respectively, which was recorded as a component of general and administrative expenses in its condensed consolidated statements of operations. At June 30, 2022, there was $51,000 of total unrecognized compensation cost related to nonvested stock option awards that is expected to be recognized over a weighted average period of 0.6 years.